Table 1.
Author | No. | Dose/Fraction | Median Follow-up (mo) | RT to Surgery Time | Chemotherapy* |
---|---|---|---|---|---|
Kosela-Paterczyk et al | 272 | 25 Gy/5 fx | 35 | 3-7 d | Yes |
Kalbasi et al | 52 | 30 Gy/5 fx | 29 | 2-6 wk | No |
Kubicek et al | 14 | 35-40 Gy/5 fx | 9.3 | 4-8 wk | Yes |
Temple et al | 42 | 30 Gy/10 fx | 72 | 4-6 wk | Yes |
Parasi et al | 16 | 30 Gy/5 fx | 10.7 | 0-7 d | Yes (1 with stage IV) |
MacDermed et al | 34 | 28 Gy/8 fx | 33.5 | 4-8 wk | Yes |
Meyer et al | 16 | 28 Gy/8 fx | 26 | Not reported | Yes |
Ryan et al | 25 | 28 Gy/8 fx | 24 | 4-5 wk | Yes |
Pennington et al | 116 | 28Gy/8 fx | 71 | 2-3 wk | Yes |
Current study | 32 | 35 Gy/5 fx | 36.4 | 4-6 wk | Yes |
Chemotherapy administered preoperatively or concurrent.
Abbreviation: fx = fractions.